The number of cancer survivors is increasing, soon to be as many of 13 million of us in the world! Bones are often affected in cancer survivors, usually a result of bone metastases, or of anti-cancer therapies which can contribute to bone loss and fragility. Bone disease in cancer survivors can result both from the [...]
Becoming a full time 24/7 caregiver for someone with any chronic illness, including advanced prostate cancer is overwhelming. Most caregivers find that they stop their own personal activities, including those that give them personal pleasure. Caregiving means subverting personal needs in favor of the needs of the patient. This situation often leads to the [...]
We are in the fortunate position because the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) continues to evolve as new agents with the ability to extend survival gain FDA approval. The most recently FDA approved treatment, the alpha emitting radiopharmaceutical radium-223 (Xofigo) was approved for men with bone metastatic prostate cancer. Most other [...]
Men who elect to have a radical prostatectomy (surgical treatment for prostate cancer) as their primary treatment often panic if they find out that they had positive surgical margins (PSMs). Positive surgical margins are an indication for the use of adjuvant radiotherapy. Despite this automatic response the association between PSMs and prostate cancer-specific mortality (CSM) [...]
Castate resistant metastatic prostate cancer (mRPC) withvisceral disease (tumors involving the internal organs of the body, specifically those within the chest (as the heart or lungs) or abdomen (as the liver, pancreas or intestines) is a negative prognostic factor. In many cases clinical trials of new investigational drugs rule out men with visceral disease from [...]